Xerostomia – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Xerostomia (Mouth and Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Xerostomia (Mouth and Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Xerostomia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 5 and 1 respectively.
Xerostomia (Mouth and Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Report Coverage
- Xerostomia – Overview
- Xerostomia – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Xerostomia – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Xerostomia – Companies Involved in Therapeutics Development
- Capricor Therapeutics Inc
- Cellix Bio Pvt Ltd
- Humanetics Corp
- Icure Pharmaceutical Inc
- Lamellar Biomedical Ltd
- MeiraGTx Holdings Plc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/88fvww/xerostomia?w=4